New drug trial targets Tough-to-Treat blood cancer after other treatments fail
NCT ID NCT07061951
Summary
This study is testing an oral drug called mirdametinib for adults with chronic lymphocytic leukemia (CLL) or a related lymphoma that has returned or stopped responding to standard treatments. The drug aims to block a specific signal that tells cancer cells to grow, potentially slowing or stopping the disease. The main goal is to see how well the drug works and how safe it is for patients who have already tried at least two other types of therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber - Harvard Cancer Center LAO
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.